Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?

被引：0
|
作者：
Erica O. Miller
Ronald G. Schwartz
机构：
[1] University of Rochester Medical Center,Cardiology Division, Department of Medicine
[2] University of Rochester Medical Center,Nuclear Medicine Division, Department of Imaging Sciences
来源：
Journal of Nuclear Cardiology | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：119 / 121
页数：2
相关论文
共 50 条
  • [1] Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?
    Miller, Erica O.
    Schwartz, Ronald G.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 119 - 121
  • [2] Safety of Regadenoson in Patients with End-Stage Renal Disease
    Aljaroudi, Wael
    Hermann, Daniel
    Hage, Fadi
    Heo, Jaekyeong
    Iskandrian, Ami E.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (01): : 133 - 135
  • [3] Safety of Regadenoson in Patients With End-Stage Renal Disease
    Aljaroudi, Wael
    Hermann, Danny
    Hage, Fadi
    Iskandrian, Ami E.
    CIRCULATION, 2009, 120 (18) : S493 - S493
  • [4] The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease
    Rami Doukky
    Ibtihaj Fughhi
    Tania Campagnoli
    Marwan Wassouf
    Amjad Ali
    Journal of Nuclear Cardiology, 2017, 24 : 112 - 118
  • [5] The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease
    Doukky, Rami
    Fughhi, Ibtihaj
    Campagnoli, Tania
    Wassouf, Marwan
    Ali, Amjad
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 112 - 118
  • [6] Cardiovascular risk in diabetic end-stage renal disease patients
    Wang, Angela Yee-Moon
    JOURNAL OF DIABETES, 2011, 3 (02) : 119 - 131
  • [7] Cardiovascular disease in end-stage renal disease patients
    Collins, AJ
    Li, SL
    Ma, JZ
    Herzog, C
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S26 - S29
  • [8] Dose escalation of ibandronate is well tolerated in patients with multiple myeloma and end-stage renal disease
    Henrich, D. M.
    Bergner, R.
    Hoffmann, M.
    Uppenkamp, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 206 - 206
  • [9] METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE RISK IN END-STAGE RENAL DISEASE PATIENTS
    Coimbra, S.
    Reis, F.
    Nunes, S.
    Viana, S.
    Rocha, S.
    Valente, M. J.
    Catarino, C.
    Rocha-Pereira, P.
    Bronze-Da-Rocha, E.
    Oliveira, J. G.
    Fernandes, J. C.
    Madureira, J.
    Faria, M. D. S.
    Miranda, V.
    Belo, L.
    Santos-Silva, A.
    ATHEROSCLEROSIS, 2022, 355 : E250 - E251
  • [10] Cardiovascular Assessment of Diabetic End-Stage Renal Disease Patients Before Renal Transplantation
    Welsh, Robert C.
    Cockfield, Sandra M.
    Campbell, Patrica
    Hervas-Malo, Marilou
    Gyenes, Gabor
    Dzavik, Vladamir
    TRANSPLANTATION, 2011, 91 (02) : 213 - 218
12345